NEKTAR THERAPEUTICS — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NEKTAR THERAPEUTICS filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $95.47M | Mar 1, 2018 |
| FY2017 | Sep 30, 2017 | $152.93M | Mar 1, 2018 |
| FY2017 | Jun 30, 2017 | $34.59M | Mar 1, 2018 |
| FY2017 | Mar 31, 2017 | $24.73M | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $37.45M | Mar 1, 2018 |
| FY2017 | Sep 30, 2016 | $36.34M | Mar 1, 2018 |
| FY2017 | Jun 30, 2016 | $32.77M | Mar 1, 2018 |
| FY2017 | Mar 31, 2016 | $58.88M | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $39.37M | Mar 1, 2017 |
| FY2016 | Sep 30, 2015 | $59.95M | Mar 1, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.23M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $98.43M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $90.12M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $92.06M | Mar 5, 2024 |
| FY2021 | Dec 31, 2021 | $25.01M | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | $24.92M | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | $28.33M | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | $23.65M | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | $23.46M | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | $30.03M | Mar 1, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $623.0K | Feb 29, 2012 |
| FY2011 | Sep 30, 2011 | $2.64M | Feb 29, 2012 |
| FY2011 | Jun 30, 2011 | $501.0K | Feb 29, 2012 |
| FY2011 | Mar 31, 2011 | ($789.0K) | Feb 29, 2012 |
| FY2011 | Dec 31, 2010 | $463.0K | Feb 29, 2012 |
| FY2011 | Sep 30, 2010 | ($760.0K) | Feb 29, 2012 |
| FY2011 | Jun 30, 2010 | $4.51M | Feb 29, 2012 |
| FY2011 | Mar 31, 2010 | ($2.47M) | Feb 29, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($164.08M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($118.96M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($276.06M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($368.20M) | Mar 5, 2024 |
| FY2021 | Dec 31, 2021 | ($145.65M) | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | ($129.71M) | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | ($125.52M) | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | ($122.97M) | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | ($117.20M) | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | ($108.59M) | Mar 1, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($140.10M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($105.20M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($263.68M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($376.17M) | Mar 5, 2024 |
| FY2021 | Dec 31, 2021 | ($112.91M) | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | ($113.60M) | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | ($110.21M) | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | ($109.39M) | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | ($110.72M) | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | ($103.05M) | Mar 1, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $117.33M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $120.91M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $114.16M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $218.32M | Mar 5, 2024 |
| FY2021 | Dec 31, 2021 | $99.61M | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | $103.74M | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | $101.31M | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | $95.60M | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | $102.72M | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | $100.53M | Mar 1, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($208.51M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($175.71M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($192.61M) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($304.01M) | Mar 5, 2024 |
| FY2023 | Dec 31, 2021 | ($412.66M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | ($313.29M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($328.68M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $718.21M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | ($80.41M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | ($117.02M) | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $171.0K | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.47M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $865.0K | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $5.68M | Mar 5, 2024 |
| FY2023 | Dec 31, 2021 | $14.99M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | $7.26M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $26.29M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $14.24M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $9.68M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $6.39M | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $280.41M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $303.85M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $398.03M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $710.60M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $1.12B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $1.54B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $1.98B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $2.15B | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $508.87M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $568.87M | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $190.57M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $243.11M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $267.05M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $343.96M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $437.68M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $461.47M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $571.97M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $432.60M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $421.04M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $480.75M | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.83M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $60.74M | Mar 13, 2026 |
| FY2025 | Dec 31, 2023 | $130.99M | Mar 13, 2026 |
| FY2024 | Dec 31, 2022 | $366.64M | Mar 14, 2025 |
| FY2023 | Dec 31, 2021 | $679.51M | Mar 5, 2024 |
| FY2023 | Dec 31, 2020 | $1.08B | Mar 5, 2024 |
| FY2022 | Dec 31, 2019 | $1.41B | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | $1.72B | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $87.83M | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | $88.13M | Feb 28, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $0 | Mar 14, 2025 |
| FY2024 | Dec 31, 2022 | $76.50M | Mar 14, 2025 |
| FY2022 | Dec 31, 2021 | $76.50M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $76.50M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $76.50M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $76.50M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $76.50M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $76.50M | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $76.50M | Mar 1, 2017 |
| FY2015 | Dec 31, 2014 | $76.50M | Feb 29, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.76B) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($3.60B) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($3.48B) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | ($3.20B) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($2.83B) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($2.31B) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($1.86B) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($1.42B) | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | ($2.12B) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($2.02B) | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.12M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $44.25M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $35.28M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | $88.23M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $25.22M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $198.96M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $96.36M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $194.91M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $4.76M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $59.64M | Mar 1, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (9) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | (8) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 5, 2024 |
| FY2021 | Dec 31, 2021 | (790) | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | (700) | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | (690) | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | (680) | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Mar 1, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (9) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | (8) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 5, 2024 |
| FY2021 | Dec 31, 2021 | (790) | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | (700) | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | (690) | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | (680) | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Mar 1, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 20.38M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | 12.39M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | 191.38M | Mar 14, 2025 |
| FY2023 | Dec 31, 2022 | 188.56M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 185.47M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 180.09M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 176.51M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 173.53M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | 159.52M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 153.21M | Mar 1, 2018 |